{
    "nctId": "NCT02124902",
    "briefTitle": "Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity",
    "officialTitle": "A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery",
    "overallStatus": "TERMINATED",
    "conditions": "Triple Negative Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 148,
    "primaryOutcomeMeasure": "Pathological Complete Response (pCR) Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Newly diagnosed AJCC7 clinical stage II or III breast cancer with complete surgical excision of the breast cancer after neoadjuvant chemotherapy as the treatment goal.\n* Patients with PR+ tumors are allowed.\n* HER2 negative by FISH or IHC staining 0 or 1+.\n* ER less than Allred score of 3 or less than 1% positive staining cells in the invasive component of the tumor\n* Tumor size at least 2cm in one dimension by clinical or radiographic exam (WHO criteria). Patients with palpable lymph nodes may be enrolled regardless of tumor size.\n* At least 18 years of age.\n* ECOG performance status \u2264 2\n* Normal bone marrow and organ function as defined below:\n\n  * Leukocytes \u2265 3,000/mcL\n  * Absolute neutrophil count \u2265 1,500/mcl\n  * Platelets \u2265 100,000/mcl\n  * Serum bilirubin within (or under ) normal limits (OR total bilirubin \u2264 3.0 x IULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome)\n  * AST(SGOT)/ALT(SGPT) within (or under ) normal limits\n  * Creatinine clearance \u2265 60 mL/min/1.73 m2\n* Patients may be pre- or post-menopausal. Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.\n* Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).\n* Able to tolerate PET/MRI with intravenous contrast administration and must complete the applicable MRI screening evaluation form\n\nExclusion Criteria:\n\n* Prior systemic therapy for the indexed breast cancer.\n* A history of other malignancy \u2264 5 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix.\n* Patients with bilateral or inflammatory breast cancer.\n* Currently receiving any other investigational agents.\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel or carboplatin.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Pregnant and/or breastfeeding. Patient must have a negative serum pregnancy test within 7 days of study entry if premenopausal.\n* Known HIV-positivity.\n* Sentinel lymph node biopsy\n* Renal insufficiency (glomerular filtration rate (GFR) \\< 30 mL/min/1.73 m2) measured within the past 60 days which precludes safe administration of the contrast agent\n* On dialysis\n* Prior allergic reaction to gadolinium-based MR contrast agents",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}